Sec. 20-631. Collaborative drug therapy management agreements between pharmacist employed by a hospital or nursing home facility and one or more physicians. Regulations.
Sec. 20-631. Collaborative drug therapy management agreements between
pharmacist employed by a hospital or nursing home facility and one or more physicians. Regulations. (a)(1) One or more pharmacists licensed under this chapter who
are determined eligible in accordance with subsection (c) of this section, and employed
by a hospital may enter into a written protocol-based collaborative drug therapy management agreement with one or more physicians licensed under chapter 370 to manage the
drug therapy of individual patients receiving inpatient services in a hospital licensed
under chapter 368v, in accordance with subsections (b) to (d), inclusive, of this section
and subject to the approval of the hospital. Each patient's collaborative drug therapy
management shall be governed by a written protocol specific to that patient established
by the treating physician in consultation with the pharmacist.
(2) One or more pharmacists licensed under this chapter who are determined eligible
in accordance with subsection (c) of this section and employed by or under contract
with a nursing home facility, as defined in section 19a-521, may enter into a written
protocol-based collaborative drug therapy management agreement with one or more
physicians licensed under chapter 370 to manage the drug therapy of individual patients
receiving services in a nursing home facility, in accordance with subsections (b) to (d),
inclusive, of this section and subject to the approval of the nursing home facility. Each
patient's collaborative drug therapy management shall be governed by a written protocol
specific to that patient established by the treating physician in consultation with the
pharmacist. Each such protocol shall be reviewed and approved by the active organized
medical staff of the nursing home in accordance with the requirements of section 19-13-D8t(i) of the Public Health Code.
(3) One or more pharmacists licensed under this chapter who are determined eligible
in accordance with subsection (c) of this section and employed by or under contract
with a hospital licensed under chapter 368v may enter into a written protocol-based
collaborative drug therapy management agreement with one or more physicians licensed
under chapter 370 to manage the drug therapy of individual patients receiving outpatient
hospital care or services for diabetes, asthma, hypertension, hyperlipidemia, osteoporosis, congestive heart failure or smoking cessation, including patients who qualify as
targeted beneficiaries under the provisions of Section 1860D-4(c)(2)(A)(ii) of the federal Social Security Act, in accordance with subsections (b) to (d), inclusive, of this
section and subject to the approval of the hospital. Each patient's collaborative drug
therapy management shall be governed by a written protocol specific to that patient
established by the treating physician in consultation with the pharmacist.
(b) A collaborative drug therapy management agreement may authorize a pharmacist to implement, modify or discontinue a drug therapy that has been prescribed for a
patient, order associated laboratory tests and administer drugs, all in accordance with
a patient-specific written protocol. In instances where drug therapy is discontinued, the
pharmacist shall notify the treating physician of such discontinuance no later than
twenty-four hours from the time of such discontinuance. Each protocol developed, pursuant to the collaborative drug therapy management agreement, shall contain detailed
direction concerning the actions that the pharmacist may perform for that patient. The
protocol shall include, but need not be limited to, (1) the specific drug or drugs to be
managed by the pharmacist, (2) the terms and conditions under which drug therapy may
be implemented, modified or discontinued, (3) the conditions and events upon which
the pharmacist is required to notify the physician, and (4) the laboratory tests that may
be ordered. All activities performed by the pharmacist in conjunction with the protocol
shall be documented in the patient's medical record. The pharmacist shall report at least
every thirty days to the physician regarding the patient's drug therapy management.
The collaborative drug therapy management agreement and protocols shall be available
for inspection by the Departments of Public Health and Consumer Protection. A copy
of the protocol shall be filed in the patient's medical record.
(c) A pharmacist shall be responsible for demonstrating, in accordance with this
subsection, the competence necessary for participation in each drug therapy management agreement into which such pharmacist enters. The pharmacist's competency shall
be determined by the hospital or nursing home facility for which the pharmacist is
employed. A copy of the criteria upon which the hospital or nursing home facility determines competency shall be filed with the Commission of Pharmacy.
(d) The Commissioner of Public Health, in consultation with the Commissioner of
Consumer Protection, may adopt regulations, in accordance with chapter 54, concerning
the minimum content of the collaborative drug therapy management agreement and the
written protocol and as otherwise necessary to carry out the purpose of this section.
(P.A. 02-41, S. 1; P.A. 03-164, S. 1; June 30 Sp. Sess. P.A. 03-6, S. 146(c), (d); P.A. 04-169, S. 17; 04-189, S. 1; P.A.
05-217, S. 1.)
History: (Revisor's note: In codifying this section the Revisors editorially changed two references in Subsec. (b) from
"pharmacists" to "pharmacist" for consistency); P.A. 03-164 amended Subsec. (a) by designating existing provisions as
Subdiv. (1), making a technical change therein, and adding Subdiv. (2) allowing pharmacists employed by nursing home
facilities to enter into collaborative drug therapy management agreement, and made conforming changes in Subsec. (c);
June 30 Sp. Sess. P.A. 03-6 and P.A. 04-169 replaced Commissioner and Department of Consumer Protection with Commissioner and Department of Agriculture and Consumer Protection, effective July 1, 2004; P.A. 04-189 repealed Sec. 146 of
June 30 Sp. Sess. P.A. 03-6, thereby reversing the merger of the Departments of Agriculture and Consumer Protection,
effective June 1, 2004; P.A. 05-217 amended Subsec. (a) by adding Subdiv. (3) allowing hospital pharmacists to enter into
collaborative drug therapy management agreements to manage drug therapy of patients receiving outpatient hospital care
or services for diabetes, asthma, hypertension, hyperlipidemia, osteoporosis, congestive heart failure or smoking cessation.